Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Copenhagen Stock Exchange  >  Novo Nordisk A/S    NOVO.B   DK0060534915

News SummaryMost relevantAll newsSector news 

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

04/13/2012 | 04:15am US/Eastern
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
React to this article
Latest news on NOVO NORDISK A/S
11/27 NOVO NORDISK A/S : production plants to be 100 percent sustainable by 2020
11/26DJMERRION PHARMACEUTICALS : Sells IP Assets To Novo Nordisk For $3 Million
11/25 NOVO NORDISK A/S : Study Results from Novo Nordisk Broaden Understanding of Drug..
11/25 NOVO NORDISK A/S : Patent Issued for Low Friction Systems and Devices (USPTO 918..
11/25 NOVO NORDISK A/S : Patent Issued for Human Insulin Analogues and Derivatives Com..
11/24DJNOVO NORDISK A/S : Says All Production Plants Will Run on Renewable Power by 202..
11/24 NOVO NORDISK A/S : All Novo Nordisk production plants to run on renewable power ..
11/24 8 Influential Insights on Effective Social Media Campaigns in Big Pharma
11/24 NOVO NORDISK A/S : All Novo Nordisk production plants to run on renewable power ..
11/23 NOVO NORDISK A/S : University of Birmingham - Diabetes drug could be used to com..
News chart
Full-screen chart
Income Statement Evolution
More Financials